4. Issues of Ethnopharmacology in HIV Management
References
Centers for Disease Control and Prevention. HIV-2 Infection Surveillance—United States, 1987-2009. MMWR Morb Mortal Wkly Rep. 2011;60:985-988.
De Cock KM, Porter A, Kouadio J, et al. Cross-reactivity on Western blots in HIV-1 and HIV-2 infections. AIDS. 1991;5:859-863.
De Cock KM, Brun-Vézinet F, Soro B. HIV-1 and HIV-2 infections and AIDS in West Africa. AIDS. 1991;5:S21-S8.
Ntemgwa ML, d'Aquin Toni T, Brenner BG, Camacho RJ, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother. 2009;53:3611-3619.
Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency virus derived from gorillas. Nat Med. 2009;15:871-872.
World Health Organization. Immunization, vaccines and biological; HIV/AIDS. Available at: http://www.who.int/immunization/topics/hiv/en/index1.html. Accessed March 19, 2012.
Burke DS. Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis. 1997;3:253-259.
Le Vu S, Le Strat Y, Barin F, et al. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis. 2010;10:682-687.
Chalmet K, Staelens D, Blot S, et al. Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections. BMC Infect Dis. 2010;10:262.
Fox J, Castro H, Kaye S, et al. Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS. 2010;24:2397-2401.
Bobkov AF, Kazennova EV, Selimova LM, et al. Temporal trends in the HIV-1 epidemic in Russia: predominance of subtype A. J Med Virol. 2004;74:191-196.
Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008;197:707-713.
Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis. 2007;195:1177-1180.
Kanki PJ, Hamel DJ, Sankalé JL, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis. 1999;179:68-73.
Nelson KE, Costello C, Suriyanon V, Sennun S, Duerr A. Survival of blood donors and their spouses with HIV-1 subtype E (CRF01 A_E) infection in northern Thailand, 1992-2007. AIDS. 2007;21:S47-S54.
Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, Nelson KE. The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS. 2007;21 Suppl 6:S39-S46.
Costello C, Nelson KE, Suriyanon V, et al. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol. 2005;34:577-584.
Taylor BS, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med. 2008;359:1965-1966.
Bhoopat L, Eiangleng L, Rugpao S, et al. In vivo identification of Langerhans and related dendritic cells infected with HIV-1 subtype E in vaginal mucosa of asymptomatic patients. Mod Pathol. 2001;14:1263-1269.
Essex M. Human immunodeficiency viruses in the developing world. Adv Virus Res. 1999;53:71-88.
Pope M, Frankel SS, Mascola JR, et al. Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. J Virol. 1997;71:8001-8007.
Dittmar MT, Simmons G, Hibbitts S, et al. Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups. J Virol. 1997;71:8008-8013.
Yang C, Li M, Newman RD, et al. Genetic diversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission. AIDS. 2003;17:1667-1674.
Blackard JT, Renjifo B, Fawzi W, et al. HIV-1 LTR subtype and perinatal transmission. Virology. 2001;287:261-265.
Renjifo B, Gilbert P, Chaplin B, et al. Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS. 2004;18:1629-1636.
Murray MC, Embree JE, Ramdahin SG, Anzala AO, Njenga S, Plummer FA. Effect of human immunodeficiency virus (HIV) type 1 viral genotype on mother-to-child transmission of HIV-1. J Infect Dis. 2000;181:746-749.
Tranchat C, Van de Perre P, Simonon-Sorel A, et al. Maternal humoral factors associated with perinatal human immunodeficiency virus type-1 transmission in a cohort from Kigali, Rwanda, 1988-1994. J Infect. 1999;39:213-220.
Tàpia N, Franco S, Puig-Basagoiti F, et al. Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission. J Gen Virol. 2003;84(Pt 3):607-613.
Martínez AM, Hora VP, Santos AL, et al. Determinants of HIV-1 mother-to-child transmission in Southern Brazil. An Acad Bras Cienc. 2006;78:113-121.
Holguín A, Gutiérrez M, Portocarrero N, Rivas P, Baquero M. Performance of OraQuick Advance Rapid HIV-1/2 Antibody Test for detection of antibodies in oral fluid and serum/plasma in HIV-1+ subjects carrying different HIV-1 subtypes and recombinant variants. J Clin Virol. 2009;45:150-152.
Weber B. A new automated fourth-generation HIV screening assay with sensitive antigen detection module and high specificity. Methods Mol Biol. 2005;304:245-255.
World Health Organization/UNAIDS. Guidance on provider-initiated HIV testing and counseling in health facilities. Switzerland;2007. Available at: http://www.who.int/hiv/pub/vct/pitc/en/index.html. Accessed March 19, 2012.
Malm K, von Sydow M, Andersson S. Performance of three automated fourth-generation combined HIV antigen/antibody assays in large-scale screening of blood donors and clinical samples. Transfus Med. 2009;19:78-88.
Pumarola T, Freeman J, Saxton E, Dillon P, Bal T, van Helden J. Performance evaluation of the ADVIA Centaur® HIV Ag/Ab combo assay. J Virol Methods. 2010;170:16-20.
Ciccaglione AR, Miceli M, Pisani G, et al. Improving HIV-2 detection by a combination of serological and nucleic acid amplification test assays. J Clin Microbiol. 2010;48:2902-2908.
World Health Organization. HIV assays: operational characteristics; report 16: rapid assays. Geneva, Switzerland; 2009. Available at: http://www.who.int/diagnostics_laboratory/evaluations/hiv/en/. Accessed March 19, 2012.
Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther. 2004;9:3-12.
Martínez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev. 2008;10:212-223.
Holguín A, López M, Molinero M, Soriano V. et al. Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol. 2008;46:2918-2923.
Rouet F, Rouzioux C. The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin Lab. 2007;53:135-148.
Gottlieb GS, Eholié SP, Nkengasong JN, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS. 2008;22:2069-2072.
Peterson K, Jallow S, Rowland-Jones SL, de Silva TI. Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. AIDS Res Treat. 2011;2011:463704.